stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Return on equity
AxoGen, Inc.'s return on equity over the twelve months to 30 September 2026 was −10.4%, up 3.1 percentage points from fiscal 2025 (−13.5%). Over the past ten years it has ranged from −124.7% (fiscal 2016) to 875.8% (fiscal 2015); the current reading is higher than 82% of that period. That is in line with the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −13.5% | (3.50) |
| FY2024 | −9.99% | 12.09 |
| FY2023 | −22.1% | 5.03 |
| FY2022 | −27.1% | (4.21) |
| FY2021 | −22.9% | (4.27) |
| FY2020 | −18.6% | 2.25 |
| FY2019 | −20.9% | 5.14 |
| FY2018 | −26.0% | 26.07 |
| FY2017 | −52.1% | 72.59 |
| FY2016 | −124.7% | (1,000.48) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| TMDX TransMedics Group, Inc. compare | 31.9% |
| INSP Inspire Medical Systems, Inc. compare | 13.5% |
| ITGR Integer Holdings Corporation compare | 5.97% |
| UFPT UFP Technologies, Inc. compare | 0.00% |
| NEOG Neogen Corporation compare | −2.67% |
| AXGN AxoGen, Inc. | −10.4% |
| IRTC iRhythm Holdings, Inc. compare | −25.8% |
| ALMR Alamar Biosciences, Inc. compare | −64.5% |
| ESTA Establishment Labs Holdings Inc. compare | −175.3% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement